Keros gives Hansoh subsidiary license for lead drug in $190M+ deal; Vaccitech snaps up new tools in small buyout
Massachusetts biotech Keros Therapeutics now has a deal with Hansoh Healthtech, a Hansoh Pharmaceutical Group subsidiary, in the form of an exclusive license.
The deal was announced earlier this week, with Hansoh getting the license from Keros to develop, manufacture and commercialize KER-050 within China, Hong Kong and Macau.
KER-050, an engineered ligand trap and Keros’ lead drug candidate, is in Phase II trials for myelodysplastic syndrome and a bone marrow cancer known as myelofibrosis. The drug is designed to increase the production of platelets and red blood cells and treat low blood cell counts such as anemia, according to Keros.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.